NANO-ADJUVANT Engineered Nanomaterials as Adjuvants to Boost Neuroblastoma Vaccine Efficacy
- Coordinator
- Royal College of Surgeons in Ireland, Ireland
- Runs
- 2 January 2026 to 1 April 2028
- Status
- Running
- EU funding
- €269k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101206792
What the project is doing
In the project's own words, from its summary on CORDIS.
Neuroblastoma (NB) is a rare, aggressive malignancy primarily affecting children under the age of 5. Despite significant advancements in treating NB, the disease remains a formidable challenge. A promising approach for NB treatment is the development of therapeutic cancer vaccines with innovative nanomaterial-based adjuvants. When used as adjuvants, nanomaterials offer several advantages, including efficient migration to lymph nodes, improved antigen presentation by dendritic cells, and cross-presentation to cytotoxic T cells.
Numerous ongoing clinical trials for NB vaccines are investigating the combination of multiple adjuvants to enhance immune responses against target antigens. NANO-ADJUVANT focuses on developing innovative nanomaterial-based adjuvants, incorporating immune-stimulating elements to enhance anti-tumor immune responses. Using my expertise in nanomaterial formulations, I will develop novel selenium-based nanoparticles incorporating manganese and zinc.
These nano-adjuvants will be designed to elicit balanced antibody and cell-mediated immune responses when combined with tumour-associated peptides. Mentor, Dr Piskareva’s experience in NB will be utilised for in vitro and in vivo studies to assess vaccine efficacy. During a secondment to Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Spain, I will perform the preclinical evaluation of vaccine efficacy in a NB mouse model under the guidance of Dr Segura.
To characterise anti-tumour immune response at the molecular and cellular level, I will use the expertise of Centre for Systems Medicine (CSM) in my host institution (RCSI) by performing scRNA-seq and bioinformatics analysis. NANO-ADJUVANT aligns with Europe's Beating Cancer Plan, which prioritises improving outcomes for children with cancer. By developing innovative adjuvant formulations, NANO-ADJUVANT contributes to enhancing NB treatment and improving patient's quality of life.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Royal College of Surgeons in Ireland | Dublin 2 | Ireland | Coordinator |
| Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Barcelona | Spain | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI